Movement Alert｜GENSCRIPT BIO Rises 3.7% in Regular Trading, AI Pharma Delivery and CARVYKTI Sales Surge Continue to Drive Momentum

Market Focus

Aug 13

On August 13, GENSCRIPT BIO rose 3.7% in regular trading, trading at HKD 25.82/share, with turnover of HKD 408 million, extending its recent strong performance.

On the news front, multiple positive catalysts continue to drive the stock. Associate company Legend Biotech reported CARVYKTI Q2 net trade sales of approximately USD 657 million, representing a 49.4% year-over-year increase, with first-half sales reaching USD 1.254 billion, up 55.1% year-over-year. Meanwhile, global AI-driven drug development is entering a commercialization phase, with US-listed Twist Bioscience reporting better-than-expected interim results and AI-related orders doubling year-over-year. GENSCRIPT BIO's life sciences business group, covering DNA synthesis, protein production, antibody development, and functional validation, recorded revenue of USD 522 million, up 14.8% year-over-year. Additionally, the company's board will convene on August 15 to review interim results and consider dividend arrangements, with market expectations remaining optimistic.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1189486757"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189486757\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189486757?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189486757","market":"us","top_or_hot":-1,"title":"Movement Alert｜GENSCRIPT BIO Rises 3.7% in Regular Trading, AI Pharma Delivery and CARVYKTI Sales Surge Continue to Drive Momentum","media":"Market Focus","content":"<p><p>On August 13, GENSCRIPT BIO rose 3.7% in regular trading, trading at HKD 25.82/share, with turnover of HKD 408 million, extending its recent strong performance.</p><p>On the news front, multiple positive catalysts continue to drive the stock. Associate company Legend Biotech reported CARVYKTI Q2 net trade sales of approximately USD 657 million, representing a 49.4% year-over-year increase, with first-half sales reaching USD 1.254 billion, up 55.1% year-over-year. Meanwhile, global AI-driven drug development is entering a commercialization phase, with US-listed Twist Bioscience reporting better-than-expected interim results and AI-related orders doubling year-over-year. GENSCRIPT BIO's life sciences business group, covering DNA synthesis, protein production, antibody development, and functional validation, recorded revenue of USD 522 million, up 14.8% year-over-year. Additionally, the company's board will convene on August 15 to review interim results and consider dividend arrangements, with market expectations remaining optimistic.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENSCRIPT BIO Rises 3.7% in Regular Trading, AI Pharma Delivery and CARVYKTI Sales Surge Continue to Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENSCRIPT BIO Rises 3.7% in Regular Trading, AI Pharma Delivery and CARVYKTI Sales Surge Continue to Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-13 10:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 13, GENSCRIPT BIO rose 3.7% in regular trading, trading at HKD 25.82/share, with turnover of HKD 408 million, extending its recent strong performance.</p><p>On the news front, multiple positive catalysts continue to drive the stock. Associate company Legend Biotech reported CARVYKTI Q2 net trade sales of approximately USD 657 million, representing a 49.4% year-over-year increase, with first-half sales reaching USD 1.254 billion, up 55.1% year-over-year. Meanwhile, global AI-driven drug development is entering a commercialization phase, with US-listed Twist Bioscience reporting better-than-expected interim results and AI-related orders doubling year-over-year. GENSCRIPT BIO's life sciences business group, covering DNA synthesis, protein production, antibody development, and functional validation, recorded revenue of USD 522 million, up 14.8% year-over-year. Additionally, the company's board will convene on August 15 to review interim results and consider dividend arrangements, with market expectations remaining optimistic.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1189486757","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189486757","pubTimestamp":1786588545,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 13, GENSCRIPT BIO rose 3.7% in regular trading, trading at HKD 25.82/share, with turnover of HKD 408 million, extending its recent strong performance.On the news front, multiple positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"动态警报|金斯瑞生物常规交易上涨3.7%，人工智能制药配送和CARVYKTI销售激增继续推动势头","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On August 13, GENSCRIPT BIO rose 3.7% in regular trading, trading at HKD 25.82/share, with turnover of HKD 408 million, extending its recent strong performance.On the news front, multiple positive catalysts continue to drive the stock. Associate company Legend Biotech reported CARVYKTI Q2 net trade sales of approximately USD 657 million, representing a 49.4% year-over-year increase, with first-half sales reaching USD 1.254 billion, up 55.1% year-over-year. Meanwhile, global AI-driven drug development is entering a commercialization phase, with US-listed Twist Bioscience reporting better-than-expected interim results and AI-related orders doubling year-over-year. GENSCRIPT BIO's life sciences business group, covering DNA synthesis, protein production, antibody development, and functional validation, recorded revenue of USD 522 million, up 14.8% year-over-year. Additionally, the company's board will convene on August 15 to review interim results and consider dividend arrangements, with market expectations remaining optimistic.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}